5. • nonacetylated prodrug of salicylate
• Obesity chronic inflammation role of anti-inflammatory agents
• Therapeutic doses of upto 4 g/day
Goldfine AB, FonsecaV, Jablonski KA, Pyle L, Staten MA, Shoelson SE.The effects of salsalate on glycemic
control in patients with type 2 diabetes: a randomized trial. Annals of internal medicine. 2010;152(6):346–57.
6. •Inhibition of NF-k
•Inhibition of cellular kinases
•Upregulation of the heat shock response
•Increases in circulating insulin concentrations
7. • Cost
• Low incidence of hypoglycemia
• low incidence of GI side effects (it is a prodrug and does not dissociate in
acid pH of the stomach)
8. • Anakinra- improves cell function1
• Etanercept – failed to improve insulin sensitivity in patients with metabolic
syndrome2
• Inflammasome activation – field of active research3
1: Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath
MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007 Apr
12;356(15):1517-26
2. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with
the metabolic syndrome. Archives of internal medicine. 2006;166(8):902–8..
3. Grant, Ryan W., and Vishwa D. Dixit. "Mechanisms of disease: inflammasome activation and the
development of type 2 diabetes." Frontiers in Immunology 4 (2013).
9. • Used for metabolic syndrome/ type 2 DM
11 HSD 1
• Cortisone cortisol
11 HSD 2
10.
11. • Thiazolidinediones
• Fibrates inhibit11 HSD1
Adamantyltriazoles, arylsulfonamidothiazoles, anilinothiazolones-
compounds currently under investigation
12. • Acts as a glucose sensor
• Rate-controlling enzyme for hepatic glucose clearance and glycogen
synthesis
• Present in pancreas and liver
• Hepatic glucokinase entirely insulin dependent
• Inactivating mutation results in MODY 2
13.
14. • First published in nature in 2003
• Over 100 patents filed and granted since then
• Piragliatin- went to phase 2 trials – but discontinued
• Primary impact is on hepatic glucokinase- hence mainly postprandial glucose
reduction
15. •TAK-875
•Stimulates glucose dependent insulin secretion
•Type of improved sulfonylurea
•Combination use of a DPP-4 inhibitor andTAK-875 -
interesting
Alquier,Thierry, andVincent Poitout. "GPR40: good cop, bad cop?." Diabetes58.5 (2009):
1035-1036.
17. • Exubera-marketed in 2006 and discontinued in September 2007 due to poor
sales by Pfizer
• Afrezza*- ultrarapid acting meal time insulin (MannKind Corp)
Rosenstock J, Lorger DL. Gnudi L, et. al. Prandial inhaled insulin plus basal insulin
glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomized
trial Lancet 2010; 375: 2244-2253.
18.
19. • Formulation of GLP-1 onTechnosphere® particles –inhaled
• Escapes DPP4 degradation
• Does not produce the nausea and vomiting characteristic of GLP-1
analogues
27. • Consider in DM with BMI> 35
• Can be considered for Asians at lower BMI cut offs(IDF position
statement on bariatric surgery in DM- BMI 27.5 to 32.5)
• An Australian report* recommends surgery be considered if
adolescents have BMI >40 , or >35 with severe co-morbidities,
are 15 years or over & can provide informed consent
*Baur LA & Fitzgerald DA. Recommendations for bariatric surgery in adolescents in
Australia and New Zealand. J Paediatr Child Health 46, 704-707 (2010).
29. RESTRICTIVE PROCEDURES
• Creating a small gastric pouch & a degree of outlet obstruction
leading to delayed gastric emptying
• 1.VERTICAL BANDED GASTROPLASTY
• 2.ADJUSTABLE GASTRIC BANDING (LAGB )
• 3. SLEEVE GASTRECTOMY
• 4.GASTRIC PLICATION
• 5. INTRA GASTRIC BALLOON (GASTRIC BALLOON)
30. Malabsorption is achieved by creating a short gut syndrome and/or by
accomplishing distal mixing of bile and pancreatic juice with ingested
nutrients thereby reducing absorption.NOT RECOMMENDED
1. BILIOPANCREATIC DIVERSION
2. THE JEJUNAL-ILEAL BYPASS
3. ENDOLUMINAL SLEEVE
36. • Newly discovered hormone – Betatrophin
• Can be injected yearly or monthly
• Shown promising results in mice
Yi P, Park J-S, Melton DA. Betatrophin: A Hormone that Controls Pancreatic β Cell
Proliferation. Cell. 2013;153(4):747–58.
37.
38. • Using AAV (adeno associated virus vectors) transfection of skeletal muscle
with insulin and glucokinase gene
• Has been done successfully in dogs
Callejas D, Mann CJ, Ayuso E, Lage R, Grifoll I, Roca C, Andaluz A, Ruiz-de Gopegui R, Montané
J, Muñoz S, FerreT, HaurigotV, Zhou S, Ruberte J, Mingozzi F, High KA, Garcia F, Bosch F.
Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy.
Diabetes. 2013;62(5):1718–29.
O’BrienT. Gene therapy for type 1 diabetes moves a step closer to reality. Diabetes.
2013;62(5):1396–7.
39.
40. • DiaPep277
• Synthetic peptide of 24 amino acids derived from the sequence of the
human heat shock protein 60 (Hsp60)
• Immunomodulator preventing cell destruction
D.Tuccinardi, E. Fioriti, S. Manfrini, E. D'Amico, and P. Pozzilli. "DiaPep277 peptide therapy in the
context of other immune intervention trials in type 1 diabetes." Expert Opin BiolTher. 2011 July
V. A. L. Huurman, P.E. van der Meide, G. Duinkerken, S. Willemen, I.R. Cohen, D. Elias, and B.O. Roep.
“Immunological efficacy of heat shock protein 60 peptide DiaPep277TM therapy in clinical type 1
diabetes.” Clin Exp Immunol. 2008 June;152(3):488-497
43. • Autologous bone marrow derived stem celltransplantation (ABMSCT)
• Significant decrease in insulin requirement and glucagon stimulated C
peptide levels shown*
Bhansali A, A P, Walia R, Bhansali S, Gupta V, Jain A, Sachdeva N, Sharma RR, Marwaha N, Khandelwal N.
Efficacy and Safety of Autologous Bone Marrow Derived Stem Cell Transplantation in patients with Type 2 Diabetes mellitus: A randomized
placebo-controlled study.
Cell Transplant. 2013 Apr 2